Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients

• Okawa Tomoko

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

• Yamaguchi Yukie

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

• Kou Kenzen

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

• Ono Junya

  Shino-Test Corporation

• Azuma Yoshinori

  Shino-Test Corporation

• Komitsu Noriko

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

• Inoue Yusuke

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

• Kohno Masumi

  Department of Dermatology, Yokohama City University Medical Center

• Matsukura Setsuko

  Department of Dermatology, Yokohama City University Medical Center

• Kambara Takeshi

  Department of Dermatology, Yokohama City University Medical Center

• Ohta Shoichiro

  Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School

• Izuhara Kenji

  Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School

• Aihara Michiko

  Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine

Abstract

Background: Recent studies have indicated that serum levels of squamous cell carcinoma antigen (SCCA) 1 and 2 induced by type 2 cytokines such as IL-4 and IL-13, are increased in patients with atopic dermatitis (AD). However, no clinical studies have analyzed serum levels of SCCA2 in larger series of AD patients or their association with various clinical characteristics. This study was performed to clarify whether serum levels of SCCA2 are associated with disease severity and clinical phenotypes of adult AD patients. Methods: An enzyme-linked immunosorbent assay was performed to examine serum SCCA2 levels in 240 adult patients with AD and 25 healthy controls in this study. Serum SCCA2 levels were analyzed with clinical characteristics and laboratory parameters including thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), blood eosinophils, total IgE, and specific IgE (Japanese cedar pollen, Dermatophagoides farina, Candida, malassezia, Staphylococcal enterotoxin B). Expression of SCCA2 in AD eruption was examined by immunohistochemistry. The effect of treatment on serum SCCA2 was also assessed. Results: Serum SCCA2 level showed a positive correlation with disease severity, levels of TARC, LDH, eosinophil counts, and IgE levels. Robust expression of SCCA2 was detected in the supra basal keratinocytes in the epidermis of AD patients. Serial measurements of serum SCCA2 revealed decreased levels of SCCA2 after treatment for AD. Conclusions: Serum SCCA2 levels reflected disease severity and clinical type of AD. Serum SCCA2 may thus be a relevant biomarker for AD.

Journal

• Allergology International

  Allergology International 67 (1), 124-130, 2018

  Japanese Society of Allergology

Keywords

• Atopic dermatitis
• Enzyme-linked immunosorbent assay
• Immunoglobulin E
• Squamous cell carcinoma antigen
• Thymus and activation-regulated
• chemokine

Details

• CRID: 1390282679609025920
• NII Article ID: 130006322096
• DOI: 10.1016/j.alit.2017.06.016
• ISSN: 14401592
• ISSN: 13238930
• Web Site: https://api.elsevier.com/content/article/PII:S1323893017301016?httpAccept=text/xml
• Web Site: https://api.elsevier.com/content/article/PII:S1323893017301016?httpAccept=text/plain
• Web Site: https://search.jamas.or.jp/link/ui/2019170481
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed